Eversept Partners’s Amedisys AMED Stock Holding History

Eversept Partners’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-224,263	Closed	-$16.5M	–	72
2023 Q1	$16.5M	Buy	+224,263	New	+$19.4M	1.15%	18

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Eversept Partners's AMED Position: Q2 2023 in Review

Eversept Partners sold out of Amedisys (AMED) in Q2 2023, closing a stake of 224,263 shares — an estimated $16.5M sold.

Eversept Partners first reported a position in AMED in Q1 2023 and held it in 1 quarter. The position peaked at $16.5M in Q1 2023. 300 funds tracked by Wall St. Rank hold AMED as of Q2 2023.

Eversept Partners reported no remaining Amedisys position as of Q2 2023 after selling out during the quarter.
Eversept Partners sold 224,263 Amedisys shares in Q2 2023, an estimated $16.5M.
Eversept Partners first reported a position in Amedisys in Q1 2023 and held it in 1 quarter.
Eversept Partners's Amedisys position peaked at $16.5M in Q1 2023.
300 funds tracked by Wall St. Rank held Amedisys as of Q2 2023.

Based on Eversept Partners's 13F filing for Q2 2023, filed 14 Aug 2023.